Clinical trials: Liver Diseases, Alcoholic
Nonalcoholic Steatohepatitis
First-in-Human Study of SRT-015 in Healthy Subjects.
This is phase 1 first-in-human trial evaluating SRT-015 to assess safety, tolerability and pharmacokinetics. This study will be conducted in 3 parts - SAD, MAD and Food Effect with target of 96 healthy volunteers.
- Trial name
- NCT04887038
- Testing
- SRT-015
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Arterial Hypertension, Atherosclerosis Occlusive Disease
Gut Microbiota in Chronic Noncommunicable Diseases
It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control…
- Conditions
- Arterial Hypertension, Atherosclerosis Occlusive Disease, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04820556
- Where
- 2 sites in Russia
- Volunteers
- 1,084 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
Human microbiota is the set of microorganisms that, in a symbiotic way, coexist and develop in the different surfaces (skin and mucous membranes) of the human body.
- Trial name
- FMT-NASH (NCT03803540)
- Testing
- Fecal Microbiota Transplantation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Puerta de Hierro University Hospital
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
Primary Objective: To evaluate the dose response relationship of SAR425899 compared to placebo on resolution of non-alcoholic steatohepatitis (NASH) with no worsening of fibrosis in diabetic and non-diabetic patients with…
- Trial name
- Restore (NCT03437720)
- Testing
- SAR425899
- Sponsor
- Sanofi
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
NAFLD
Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease
The major adverse health consequences of obesity occur only when non-alcoholic fatty liver disease (NAFLD) also develops. NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids.
- Trial name
- NCT02558530
- Testing
- Low carbohydrate diet
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Insulin Resistance, Non-Alcoholic Fatty Liver Disease
The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance
The aim of this study is to investigate whether ingestion of curcumin will prevent hepatic insulin resistance (assessed by homeostatic model assessment of insulin resistance (HOMA-IR)) induced by short-term oral glucocorticoid…
- Trial name
- CURPRED (NCT04315350)
- Testing
- Curcumin Liposome, Prednisolone
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Non Alcoholic Fatty Liver Disease
Mastiha Treatment for Obese With NAFLD Diagnosis
NAFLD/NASH is one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients.
- Trial name
- MAST4HEALTH (NCT03135873)
- Testing
- Mastiha
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Harokopio University
Nonalcoholic Fatty Liver Disease
Time Restricted Feeding on Nonalcoholic Fatty Liver Disease ( TREATY-FLD )：a 12-month Follow-up Study
Time restricted feeding (TRF) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less.
- Trial name
- TREATY-FLD (NCT04988230)
- Testing
- Time restricted feeding, Continuous Energy Restriction
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-alcoholic Steatohepatitis
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by…
- Trial name
- NCT04722653
- Testing
- NNC0194-0499
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, PreDiabetes
Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding.
- Conditions
- Obesity, PreDiabetes, Diabetes, Hypertension
- Trial name
- NCT05309057
- Testing
- Intermittent Fasting
- Where
- 2 sites in Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Toronto
NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
The investigators use machine learning capabilities on massive electronic health records for the purpose of developing a model that prioritizes individuals at high risk of progressing to liver cirrhosis, and validating it with…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05218538
- Testing
- Fibroscan (non interventional)
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- HaEmek Medical Center, Israel
Nonalcoholic Fatty Liver Disease
Comparison of Dietary Sugar Reduction Methods
This is a two arm, randomized, 4 week study comparing 2 methods of dietary sugar reduction at Emory University and Children's Healthcare of Atlanta. Participants will be non-diabetic children with NAFLD.
- Trial name
- NCT04186793
- Testing
- Guided Grocery Shopping (GGS), Diet Provision Group
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic…
- Trial name
- RESOLVE-IT (NCT02704403)
- Testing
- Elafibranor
- Where
- 326 sites in United States, Argentina and 23 more
- Volunteers
- 2,157 people
- Sponsor
- Genfit
Fatty Liver, Fatty Liver, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with non-alcoholic fatty liver…
- Trial name
- NCT04462562
- Testing
- Quantitative US (Samsung Medison, RS85A)
- Where
- South Korea
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin…
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT04976283
- Testing
- Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
- Where
- Pakistan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic…
- Trial name
- NCT02781584
- Testing
- SEL, FIR, CILO
- Where
- 13 sites in United States, New Zealand
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Steatohepatitis, Nonalcoholic
The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
The aim of the current study is to evaluate the safety and efficay of Montelukast in treatment of patients with fatty liver disease.
- Trial name
- NCT04080947
- Testing
- Control group, Montelukast group
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Sadat City University
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.